Categories: News

Spago Nanomedical Receives Go-Ahead to Include Patients with Pancreatic Cancer in the Clinical Study SPAGOPIX-01

LUND, SWEDEN / ACCESSWIRE / February 25, 2022 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)

Spago Nanomedical AB (publ) has received approval from the Swedish Medical Products Agency to initiate recruitment of patients with pancreatic cancer for the clinical study with the contrast agent SN132D.

“By including another patient group, we can in a cost-effective way demonstrate a broader use of SN132D and build additional value in the SpagoPix project at an early clinical development stage”, said CEO Mats Hansen.

The SPAGOPIX-01 study is carried out at Sahlgrenska University Hospital in Gothenburg and the University Hospital in Uppsala. The recruitment of patients with suspected or confirmed pancreatic cancer with spread to the liver begins immediately.

SN132D is a manganese-based nanomedical contrast agent with the potential to improve the precision of cancer diagnostics with magnetic resonance imaging (MRI) and increase the efficiency of the healthcare system. Interim data from the SPAGOPIX-01 study have shown that SN132D provides clinically relevant and selective contrast enhancement in breast cancer tumors with minimal background contrast and good safety.

For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.

FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, info@fnca.se.

Attachments

Spago Nanomedical receives go-ahead to include patients with pancreatic cancer in the clinical study SPAGOPIX-01

SOURCE: Spago Nanomedical

View source version on accesswire.com:
https://www.accesswire.com/690410/Spago-Nanomedical-Receives-Go-Ahead-to-Include-Patients-with-Pancreatic-Cancer-in-the-Clinical-Study-SPAGOPIX-01

Staff

Recent Posts

MediOrbis(TM) Partners with Healthyr(TM) to Offer Proven Engagement, Longitudinal Care and Specialty

MediOrbis TM Partners with Healthyr to Offer Proven Engagement, Longitudinal Care and Specialty Telehealth Services…

1 hour ago

Humhealth Simplifies the Medicare Program With All-in-One Software

WIXOM, MI / ACCESSWIRE / June 19, 2024 / Humhealth has emerged as a software…

1 hour ago

United Global Trading Corp. Announces ShieldON(R) EcoSeries Biodegradable Nitrile Gloves

FDA-Approved Single-Use Nitrile Gloves Break Down Faster Than Conventional GlovesLONG BEACH, CA / ACCESSWIRE /…

1 hour ago

OSSIO expands portfolio of highly differentiated bio-integrative fixation implants with small compression staples to enhance bunion repair patients’ satisfaction

Revolutionary material science innovation, OSSIOfiber® continues to evolve standard of care in orthopedic surgeryWOBURN, Mass.--(BUSINESS…

4 hours ago

Pavion Acquires Signet

Expanding New England Footprint and Leadership in Critical Communications CHANTILLY, Va., June 19, 2024 /PRNewswire/…

4 hours ago

AvaSure Chief Nursing Executive Advisory Board Collaborates on Inpatient Virtual Care Maturity Model

Industry experts share insights to modernize care delivery models for the virtual nursing market BELMONT,…

4 hours ago